A new pathogenic mutation of the BRCA1 gene in a patient with ovarian cancer A case report

被引:0
作者
Niu Yizhen [1 ,2 ]
Li Kemin [1 ,2 ]
Li Qingli [1 ,2 ]
Wang Danqing [1 ,2 ]
Yin Rutie [1 ,2 ]
Song Liang [1 ,2 ]
机构
[1] Sichuan Univ, West China Univ Hosp 2, Minist Educ, Dept Gynecol & Obstet, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Univ Hosp 2, Minist Educ, Key Lab Obstet & Gynaecol & Paediat Dis & Birth D, Chengdu, Sichuan, Peoples R China
关键词
BRCA; mutation; ovarian cancer; pathogenic; GUIDELINES;
D O I
10.1097/MD.0000000000012371
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: The breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene and tumor susceptibility gene. Germ line BRCA1/2 mutations significantly increase the risk of breast cancer and other cancers in women. Patient concerns: A 48-year-old woman was diagnosed with breast cancer at the age of 42 and subsequently diagnosed with ovarian cancer at the age of 48. Her sister had a history of breast cancer and her mother died from ovarian cancer. Diagnoses: The patient has a family history of tumors. BRCA1/2 mutations was proved in this family members. Interventions: Sanger sequencing was used to evaluate the BRCA1/2 gene status of the patient and her sister to identify the genetic mutation sites. Outcomes: They had the same genetic mutation, namely, the c.3487_3488insA (p. Thr1163AsnfsX2) mutation in the BRCA1 gene, which is a novel mutation. Lessons: This novel mutation may be a new pathogenic mutation of the BRCA1 gene. Its relationship to breast and ovarian cancers needs to be further verified in more patient cases. Moreover, mutant protein functions in both cell and animal models are also needed.
引用
收藏
页数:4
相关论文
共 7 条
  • [1] Cancer of the ovary, fallopian tube, and peritoneum
    Berek, Jonathan S.
    Crum, Christopher
    Friedlander, Michael
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2012, 119 : S118 - S129
  • [2] Bristow RE, 2015, CANCER, V89, P1532
  • [3] Consortium E, 2017, ENIGMA BRCA1 2 GEN V
  • [4] Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening
    Paluch-Shimon, S.
    Cardoso, F.
    Sessa, C.
    Balmana, J.
    Cardoso, M. J.
    Gilbert, F.
    Senkus, E.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : v103 - v110
  • [5] Sequence Variant Classification and Reporting: Recommendations for Improving the Interpretation of Cancer Susceptibility Genetic Test Results
    Plon, Sharon E.
    Eccles, Diana M.
    Easton, Douglas
    Foulkes, William D.
    Genuardi, Maurizio
    Greenblatt, Marc S.
    Hogervorst, Frans B. L.
    Hoogerbrugge, Nicoline
    Spurdle, Amanda B.
    Tavtigian, Sean V.
    [J]. HUMAN MUTATION, 2008, 29 (11) : 1282 - 1291
  • [6] Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
    Richards, Sue
    Aziz, Nazneen
    Bale, Sherri
    Bick, David
    Das, Soma
    Gastier-Foster, Julie
    Grody, Wayne W.
    Hegde, Madhuri
    Lyon, Elaine
    Spector, Elaine
    Voelkerding, Karl
    Rehm, Heidi L.
    [J]. GENETICS IN MEDICINE, 2015, 17 (05) : 405 - 424
  • [7] The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients
    Wu, Xiaohua
    Wu, Lingying
    Kong, Beihua
    Liu, Jihong
    Yin, Rutie
    Wen, Hao
    Li, Ning
    Bu, Hualei
    Feng, Yanling
    Li, Qingli
    Lu, Xuesong
    Wei, Jia
    Zhu, Xuehua
    Mills, John
    Ellison, Gillian
    Gutjahr, Thorsten
    Liu, Yuzhen
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (08) : 1650 - 1657